Top Markets
#1 ADO Protocol ADO Protocol +324.24%
#2 Islamic Coin Islamic Coin +155.41%
#3 GoPlus Security GoPlus Security +59.57%
#4 Starpower Starpower +34.32%
#5 Verus Coin Verus Coin +33.01%
#6 GAIB AID GAIB AID +24.67%
#7 Casper Network Casper Network +14.40%
#8 o1.exchange o1.exchange +12.87%
#9 Status Status +12.12%
#10 Lumia Lumia +10.89%
Coin of the day
ADO Protocol ADO Protocol
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Clasificación en acciones #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Precio por acción
$0.4264
Última sincronización: 2022-09-14
Capitalización bursátil
$7.93M
Cambio (1 día)
-16.44%
Cambio (1 año)
0.00%
País
US
Comercio Caladrius Biosciences, Inc. (CLBS)

Categoría

Healthcare
Ingresos de Caladrius Biosciences, Inc. (CLBS)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Caladrius Biosciences, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Caladrius Biosciences, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE